Epigenetic therapy for ovarian cancer: promise and progress

Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of approximately 47%, a number that has remained constant over the past two decades. Early diagnosis improves survival, but unfortunately only 15% of ovarian cancers are diagnosed at an early or localized stage. Most...

Descripción completa

Detalles Bibliográficos
Autores principales: Moufarrij, Sara, Dandapani, Monica, Arthofer, Elisa, Gomez, Stephanie, Srivastava, Aneil, Lopez-Acevedo, Micael, Villagra, Alejandro, Chiappinelli, Katherine B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334391/
https://www.ncbi.nlm.nih.gov/pubmed/30646939
http://dx.doi.org/10.1186/s13148-018-0602-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334391/
https://www.ncbi.nlm.nih.gov/pubmed/30646939
http://dx.doi.org/10.1186/s13148-018-0602-0

Ejemplares similares